Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Lung Cancer Therapeutics Market size is set to grow by USD 10.52 billion from 2024-2028, Heavy contribution of immunomodulators boost the market, Technavio

      Global lung cancer therapeutics market 2024-2028

      News provided by

      Technavio

      May 27, 2024, 16:40 ET

      Share this article

      Share this article


      NEW YORK, May 27, 2024 /PRNewswire/ -- The global lung cancer therapeutics market  size is estimated to grow by USD 10.52 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  7.69%  during the forecast period. 

      For more insights on the forecast market size and historic data (2018 - 2022) - Request a sample report!

      Continue Reading
      Technavio has announced its latest market research report titled Global lung cancer therapeutics market 2024-2028
      Technavio has announced its latest market research report titled Global lung cancer therapeutics market 2024-2028

      Lung Cancer Therapeutics Market Scope

      Report Coverage

      Details

      Base year

      2023

      Historic period

      2018 - 2022

      Forecast period

      2024-2028

      Growth momentum & CAGR

      Accelerate at a CAGR of 7.69%

      Market growth 2024-2028

      USD 10527.7 million

      Market structure

      Fragmented

      YoY growth 2022-2023 (%)

      6.99

      Regional analysis

      North America, Europe, Asia, and Rest of World (ROW)

      Performing market contribution

      North America at 46%

      Key countries

      US, UK, Canada, China, and France

      Key companies profiled

      AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galecto Inc., GlaxoSmithKline Plc, IOVANCE Biotherapeutics Inc., Johnson and Johnson Services Inc., Merck and Co. Inc., Moderna Inc., Novartis AG, Parexel International Corp., Pfizer Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd.

      Market Driver

      The lung cancer therapeutics market is evolving, driven by technological advancements to provide more sophisticated treatment options for NSCLC and SCLC. Currently, chemotherapy, immunomodulators, and biological drugs are the primary treatments. Targeted therapies, such as immunomodulators, are effective but do not guarantee a cure. To address the rising lung cancer prevalence, research is ongoing to develop regenerative therapies, including gene therapies.

      Targeted agents focus on specific genetic abnormalities causing NSCLC. Key areas include nanomedicine, advanced therapeutics, and precision medicine. Lung cancer is linked to heart disease, strokes, lower respiratory infections, diabetes, and unhealthy lifestyles, including tobacco use and second-hand smoke.

      Stringent regulations govern the market, with companies like Astellas focusing on drug classes and genes. Biomarkers, radiation therapy, chemotherapy, surgery, and targeted therapy are common treatment types. High incidence rates and rising pollution levels further emphasize the need for new, effective therapies. 

      Market Challenges

      • Lung cancer is primarily treated through surgeries and radiation therapy during its early stages due to limited therapeutic effectiveness and high long-term costs. Early-stage NSCLC often does not metastasize, making surgical procedures highly effective. VATS is a less-invasive surgery used for early-stage NSCLC treatment. Lung cancer is linked to heart disease, strokes, lower respiratory infections, diabetes, and unhealthy lifestyles, including tobacco use and smoking.
      • Advanced therapeutics, such as targeted therapies and immunotherapies, and nanomedicine are emerging treatment options. Strict regulations govern the use of drugs like AdoRx Therapeutics, Avastin, Tarceva, Taxotere, and Gemzar. Cancer awareness campaigns aim to reduce deaths from lung cancer, which has a high incidence rate and is influenced by rising pollution levels.
      •  

      Research report provides comprehensive data on impact of trend, driver and challenges - Request a sample report!

      Segment Overview 

      1. Therapy 
        • 1.1 Targeted therapy
        • 1.2 Immunotherapy
        • 1.3 Chemotherapy
      2. Type 
        • 2.1 NSCLC
        • 2.2 SCLC
      3. Geography 
        • 3.1 North America
        • 3.2 Europe
        • 3.3 Asia
        • 3.4 Rest of World (ROW)

      1.1 Targeted therapy-  The lung cancer therapeutics market is segmented based on therapy types, including targeted therapies, which focus on specific genes and mutations associated with the disease. These therapies include those that target tumor blood vessel growth, such as CYRAMZA, and those that address mutations in the EGFR gene, like Tarceva, Gilotrif, IRESSA, TAGRISSO, and VIZIMPRO. Additionally, therapies for T790M mutations, ALK gene changes, and BRAF gene changes are gaining prominence.

      The segment's growth is driven by the increasing prevalence of chronic diseases like heart disease, strokes, lower respiratory infections, and diabetes, which are risk factors for lung cancer. Side effects, nanomedicine, and advanced therapeutics are key areas of research and development initiatives. Lung cancer, responsible for a significant number of deaths, is caused by unhealthy lifestyles, tobacco use, and smoking, as well as second-hand smoke.

      Stringent regulations ensure the safety and efficacy of drugs, with companies like Astellas and AdoRx Therapeutics developing new therapies. Biomarkers and radiation therapy, chemotherapy, surgery, immunotherapy, and targeted therapy are among the treatment options. The high incidence rate and rising pollution levels further fuel market growth.

      For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) - Download a Sample Report

      Research Analysis

      The Lung Cancer Therapeutics Market encompasses various treatment modalities, including Radiation Therapy, Chemotherapy, Surgery, Targeted Therapy, and Immunotherapy. Unhealthy lifestyles are a significant contributor to the rising incidences of Lung Cancer, necessitating increased Cancer Awareness. Lung Cancer therapeutics span across different Drug Classes, such as Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Chemotherapeutic Agents.

      Precision Medicine and RD initiatives play a pivotal role in the development of novel Lung Cancer therapeutics. Targeted therapies, specifically those focusing on Genes associated with Lung Carcinoid Tumors, are a promising area of research in the Lung Cancer Therapeutic landscape.

      Market Research Overview

      The Radiatology and Chemotherapy therapies play a significant role in the treatment of Lung Cancer. Surgery is also an essential therapeutic approach, especially for early-stage diagnoses. Smoking is a major risk factor for developing lung cancer, and cancer cells require energy to grow and spread, making metabolic targets an attractive area for therapeutic intervention.

      The use of targeted therapies, such as those that inhibit specific proteins or pathways, is becoming increasingly common. The market for Lung Cancer Therapeutics is vast and diverse, encompassing various types of treatments, including radiotherapy, chemotherapy, targeted therapies, and surgery. The demand for these therapies is driven by the increasing incidence and prevalence of lung cancer worldwide.

      The market is expected to grow significantly due to the ongoing research and development efforts in this field. The use of advanced technologies, such as Artificial Intelligence and Machine Learning, is also transforming the landscape of Lung Cancer Therapeutics. The long-term success of these therapies depends on their ability to improve patient outcomes and quality of life while minimizing side effects.

      Table of Contents:

      1 Executive Summary
      2 Market Landscape
      3 Market Sizing
      4 Historic Market Size
      5 Five Forces Analysis
      6 Market Segmentation

      • Therapy
        • Targeted Therapy
        • Immunotherapy
        • Chemotherapy
      • Type
        • NSCLC
        • SCLC
      • Geography
        • North America
        • Europe
        • Asia
        • Rest Of World (ROW)

      7 Customer Landscape
      8 Geographic Landscape
      9 Drivers, Challenges, and Trends
      10 Company Landscape
      11 Company Analysis
      12 Appendix

      About Technavio

      Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

      With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

      Contacts

      Technavio Research
      Jesse Maida
      Media & Marketing Executive
      US: +1 844 364 1100
      UK: +44 203 893 3200
      Email: [email protected]
      Website: www.technavio.com/

      SOURCE Technavio

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.